Transgene Completes Phase 2 Randomization for Personalized Cancer Vaccine TG4050

Overview

• Transgene, which announced Monday it finished Phase 2 randomization, enrolled 38 patients in its TG4050 Phase 1/2 trial for HPV‑negative head and neck cancer.
• TG4050 is a personalized vaccine built on Transgene’s myvac viral vector that carries a patient’s tumor mutations chosen by NEC’s AI to spur targeted T‑cell attacks.
• The trial compares giving the vaccine right after surgery and follow‑up therapy against watchful waiting to see if vaccination lowers the risk of the cancer coming back.
• The primary measure is two‑year disease‑free survival, and the company expects topline results by the end of Q1 2028.
• Early Phase 1 data showed the shots were well tolerated and sparked durable immune responses, and all treated patients were disease‑free at two years, with three‑year follow‑up due in Q2 or Q3 2026 and first Phase 2 immunology data planned for H2 2026.